Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Belgium
  4. Euronext Bruxelles
  5. Argenx SE
  6. Summary
    ARGX   NL0010832176

ARGENX SE

(ARGX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Bruxelles
06/07/2021 06/08/2021 06/09/2021 06/10/2021 06/11/2021 Date
216(c) 215(c) 236.4(c) 245.4(c) 255.4(c) Last
165 457 106 699 109 978 75 800 108 350 Volume
-2.44% -0.46% +9.95% +3.81% +4.07% Change
More quotes
Financials
Sales 2021 175 M 212 M 212 M
Net income 2021 -595 M -720 M -720 M
Net cash position 2021 1 595 M 1 930 M 1 930 M
P/E ratio 2021 -23,3x
Yield 2021 -
Sales 2022 200 M 242 M 242 M
Net income 2022 -716 M -866 M -866 M
Net cash position 2022 981 M 1 188 M 1 188 M
P/E ratio 2022 -19,0x
Yield 2022 -
Capitalization 13 103 M 15 850 M 15 858 M
EV / Sales 2021 65,8x
EV / Sales 2022 60,7x
Nbr of Employees 336
Free-Float 99,0%
More Financials
Company
argenx SE is a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases and cancer. Partnering with leading academic researchers through its Immunology Innovation Program (IIP), argenx SE aims to translate immunology breakthroughs into a world-class portfolio of novel antibody-based medicines. argenx SE is evaluating efgartigimod in multiple serious autoimmune... 
Sector
Biotechnology & Medical Research
Calendar
06/16 | 11:00amPresentation
More about the company
Ratings of argenx SE
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about ARGENX SE
06/09European ADRs Slightly Higher Wednesday With Biotechs Leading While Miners Dr..
MT
06/08ARGENX  : Baird Adjusts argenx SE's Price Target to $333 from $346, Keeps Outper..
MT
06/08ARGENX  : Goldman Sachs Adjusts Price Target for argenx SE to 235 Euros From 261..
MT
06/08ARGENX  : Wedbush Cuts Price Target on arGEN-X to $344 From $356, Maintains Outp..
MT
06/07ARGENX  : to regain global rights to cusatuzumab (Form 6-K)
PU
06/07European ADRs Nudge Lower in Monday Trading
MT
06/07SECTOR UPDATE : Health Care Stocks Gain Premarket Monday
MT
06/07ARGENX  : to Reclaim Rights to Cusatuzumab After Janssen Ends Collaboration on L..
MT
06/07Johnson & Johnson Ends Cusatuzumab License Deal With Argenx
DJ
06/07PRESS RELEASE : Innovative Molecules raises EUR20 million Series A equity financ..
DJ
06/07ARGENX  : Reclaims Global Rights For Acute Myeloid Leukemia Treatment
MT
06/07argenx to regain global rights to cusatuzumab
GL
06/01ARGENX  : Appoints Karl Gubitz as Chief Financial Officer (Form 6-K)
PU
06/01ARGENX  : Taps Karl Gubitz for Finance Chief
MT
06/01ARGENX  : Names Pfizer Executive as CFO
MT
More news
News in other languages on ARGENX SE
06/07ARGENX SE  : le cusatuzumab déçoit
06/07Zeldzame tegenvaller voor Argen-x
06/07BRUSSELS STOCK EXCHANGE : Vlakke start Bel20 aan handelsweek voorzien
06/07Argen-x krijgt rechten op cusatuzumab terug
06/01Nieuwe CFO bij Argen-x
More news
Analyst Recommendations on ARGENX SE
More recommendations
Chart ARGENX SE
Duration : Period :
argenx SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARGENX SE
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 250,00 €
Last Close Price 255,40 €
Spread / Highest target 25,3%
Spread / Average Target -2,11%
Spread / Lowest Target -19,7%
EPS Revisions
Managers and Directors
NameTitle
Tim van Hauwermeiren Chief Executive Officer & Executive Director
Eric Castaldi Chief Financial Officer
Peter K. M. Verhaeghe Chairman
Hans J. W. de Haard Chief Scientific Officer
Wim Parys Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARGENX SE5.54%15 850
GILEAD SCIENCES, INC.18.04%86 250
WUXI APPTEC CO., LTD.30.07%66 799
BIONTECH SE192.63%57 615
REGENERON PHARMACEUTICALS8.78%54 424
VERTEX PHARMACEUTICALS-18.33%49 966